Published in J Invest Dermatol on December 01, 2005
Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma (2008) 0.97
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2015) 0.89
Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol (2016) 0.87
Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma. Leuk Lymphoma (2011) 0.83
Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood (2014) 0.82
Probing the immune dysregulation in cutaneous T cell lymphomas. J Invest Dermatol (2005) 0.76
Sox9 is essential for outer root sheath differentiation and the formation of the hair stem cell compartment. Curr Biol (2005) 4.04
IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol (2010) 2.67
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol (2004) 2.33
Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. Development (2002) 2.16
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol (2007) 2.00
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol (2015) 1.98
IgG4-related skin disease successfully treated by thalidomide: a report of 2 cases with emphasis on pathological aspects. JAMA Dermatol (2013) 1.98
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol (2011) 1.85
Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. Lancet (2008) 1.73
Granuloma faciale: a clinicopathologic study of 66 patients. J Am Acad Dermatol (2005) 1.70
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A (2007) 1.68
A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood (2010) 1.67
Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin. Cytometry A (2014) 1.48
Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol (2006) 1.46
SOX9 expression is a general marker of basal cell carcinoma and adnexal-related neoplasms. J Cutan Pathol (2008) 1.33
Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis (2012) 1.32
Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol (2002) 1.32
Critical and differential roles of NKp46- and NKp30-activating receptors expressed by uterine NK cells in early pregnancy. J Immunol (2008) 1.28
CD molecules 2005: human cell differentiation molecules. Blood (2005) 1.27
CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog (2011) 1.26
CD molecules 2006--human cell differentiation molecules. J Immunol Methods (2006) 1.23
SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. J Immunol (2006) 1.21
Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res (2013) 1.16
Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cancer Inst (2011) 1.16
The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function. Eur J Immunol (2006) 1.15
Soluble CD100 functions on human monocytes and immature dendritic cells require plexin C1 and plexin B1, respectively. Int Immunol (2005) 1.13
Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood (2006) 1.13
IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A (2009) 1.11
Cutaneous Invasive Aspergillosis: Retrospective Multicenter Study of the French Invasive-Aspergillosis Registry and Literature Review. Medicine (Baltimore) (2015) 1.11
Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A (2011) 1.10
Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol (2004) 1.09
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol (2006) 1.08
Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci U S A (2002) 1.08
Histologic and immunohistologic characterization of skin localization of myeloid disorders: a study of 173 cases. Am J Clin Pathol (2011) 1.06
IgA-mediated human autoimmune hemolytic anemia as a result of hemagglutination in the spleen, but independent of complement activation and FcαRI. Blood (2010) 1.05
Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients. Mol Med (2010) 1.03
IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep (2013) 1.03
Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targets. J Biomed Biotechnol (2011) 1.02
Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol (2004) 1.02
Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. J Immunol (2004) 1.00
Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol (2014) 0.99
Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets. Blood (2009) 0.98
IL4I1: an inhibitor of the CD8⁺ antitumor T-cell response in vivo. Eur J Immunol (2011) 0.98
Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis (2013) 0.98
Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One (2012) 0.98
CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol (2004) 0.95
MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in southern European populations: results from a meta-analysis. Eur J Cancer (2012) 0.95
Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation. J Immunol (2009) 0.94
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood (2004) 0.93
Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res (2007) 0.93
A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J Exp Med (2011) 0.92
CD160: a unique activating NK cell receptor. Immunol Lett (2011) 0.92
CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. Int Immunol (2007) 0.92
Soluble HLA-G and control of angiogenesis. J Reprod Immunol (2007) 0.91
Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients. J Invest Dermatol (2010) 0.91
Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood (2012) 0.91
BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression. Int Immunol (2002) 0.90
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Hum Pathol (2013) 0.89
Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood (2011) 0.89
Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. J Invest Dermatol (2006) 0.88
Efalizumab-induced bullous pemphigoid. J Am Acad Dermatol (2010) 0.88
CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. Blood (2010) 0.87
TWEAK affects keratinocyte G2/M growth arrest and induces apoptosis through the translocation of the AIF protein to the nucleus. PLoS One (2012) 0.87
IFN-α and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proc Natl Acad Sci U S A (2011) 0.87
The CD160+ CD8high cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients. Cell Immunol (2005) 0.87
Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133. Cancers (Basel) (2011) 0.87
Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. Exp Dermatol (2010) 0.86
CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides. Exp Dermatol (2012) 0.86